BUZZ-Korro Bio plunges on trial failure, Novo Nordisk deal halt

Reuters11-13
BUZZ-<a href="https://laohu8.com/S/KRRO">Korro Bio</a> plunges on trial failure, <a href="https://laohu8.com/S/NVO">Novo Nordisk</a> deal halt

** Shares of drug developer Korro Bio KRRO.O plunge 76.1% to $7.62 in extended trading

** KRRO says its experimental drug KRRO-110 for a rare lung and liver disease produced a key protein in patients but failed to reach expected levels

** The drug was being tested in Alpha-1 Antitrypsin Deficiency, a rare inherited disorder that can cause severe lung and liver disease

** Co also pauses its licensing deal with Novo Nordisk NOVOb.CO for 12 months, effective November 11

** Co says the collaboration may yield no benefits, prompting Korro Bio to wind down its related R&D activities immediately

** KRRO says Novo Nordisk will reimburse Korro for certain wind-down costs; additionally, Korro announced a 34% workforce reduction

** KRRO stock down 17.5% YTD

(Reporting by Padmanabhan Ananthan)

((Padmanabhan.Ananthan@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment